Concordia, Par Settle With FTC Over Generic ADHD Drug Deal
Concordia Pharmaceuticals Inc. and Par Pharmaceutical Companies Inc. have agreed not to compete in the sale of a generic Attention Deficit Hyperactivity Disorder medication following an anti-competition investigation, the Federal Trade...To view the full article, register now.
Already a subscriber? Click here to view full article